相关实验视频

Updated: Apr 14, 2026

Isolation of Glomeruli and In Vivo Labeling of Glomerular Cell Surface Proteins

Isolation of Glomeruli and In Vivo Labeling of Glomerular Cell Surface Proteins

Published on: January 18, 2019

ATP6V1D的差异表达及其在IgA病中的诊断潜力

Liang Peng¹, Lin Hu², Yi-Qun Peng^3,4

¹Department of Nephrology, The Second Affiliated Hospital of the University of South China, Hengyang, 421001, China. 2023020144@usc.edu.cn.

Current medical science

|September 5, 2025

概括

尿路ATP6V1D显示为IgA脏病 (IgAN) 的非侵入性生物标志物,使其与膜性脏病 (MN) 和最小变化性疾病 (MCD) 区分开来. 在IgAN患者中,ATP6V1D的水平降低可能有助于诊断,减少组织检查的需要.

科学领域:

肝脏病学
分子生物学
生物标志物发现

背景情况:

IgA脏病 (IgAN) 是最常见的原发性质细胞疾病,但诊断需要侵入性脏活检.
需要非侵入性生物标志物来区分IgAN与膜性脏病 (MN) 和最小变化疾病 (MCD) 等其他球膜性疾病.

研究的目的:

为了确定新的尿路生物标志物用于Igan的非侵入性诊断.
使用尿路生物标志物将Igan与MN和MCD区分开来.

主要方法:

对外围血液单核细胞 (PBMC) 转录组进行分析,以确定差异表达基因 (DEG) 和枢纽基因.
在PBMC,尿液和脏组织中验证ATP6V1D表达,使用ELISA,西式涂抹和免疫染色.
尿中ATP6V1D,银河糖缺乏IgA1 (GD-IgA1) 和临床参数的相关性分析;用于诊断准确性的ROC曲线分析.

主要成果:

鉴定出ATP6V1D是一种关键的枢纽基因,参与ATPase活性和与溶酶相关的通路.
与健康对照组,MCD和MN患者相比,Igan患者的PBMC,尿液和脏组织中观察到较低的ATP6V1D水平.
尿中的ATP6V1D和GD-IgA1在区分IGAN与MN和MCD方面表现出很高的准确性 (AUC> 0. 95).

结论:

尿液中的ATP6V1D度是区分Igan与MN和MCD的潜在非侵入性生物标志物.
ATP6V1D水平与疾病活性相关,在IgAN诊断中的临床应用具有前景.

关键词:

生物标志物抗体A脏病膜性病最少变化的疾病周围血液单核细胞

更多相关视频

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

相关概念视频

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...